Heikki Lanckriet

Heikki is a biochemical engineer with a passion for combining the worlds of scientific innovation and business. After having founded his own company 19 years ago, he has focussed on building, growing and investing in innovative life science companies. He is currently the CEO of, and a significant shareholder in, 4basebio, an AIM listed company focussing on next generation gene therapies. Prior to this, Heikki led Expedeon, a German listed life sciences company. In 2020 Heikki concluded the sale to Abcam plc for €120m of Expedeon’s proteomics and immunology business; and the subsequent rebranding and refocus of the company to 2Invest AG, an investment company with a focus on the life science sector. Heikki continues to be heavily involved in the science also acting as CSO for 4basebio and Expedeon previously. He holds a Bachelor’s and Master’s degree in Biochemical Engineering from the University of Ghent, Belgium and a PhD in Chemical Engineering from the University of Cambridge, UK. He has also published papers in high impact peer-reviewed international scientific journals and is named inventor on a multitude of patents.